<DOC>
	<DOCNO>NCT01829503</DOCNO>
	<brief_summary>Primary objective : To determine efficacy induction regimen use decitabine epigenetic primer follow cytarabine treatment old patient newly diagnose Acute myeloid leukemia ( AML ) . Primary endpoint : Complete remission rate Secondary objective : To determine safety induction regimen decitabine follow cytarabine treatment old patient newly diagnose AML , evaluate survival identify potential predictive factor response treatment Secondary endpoint : - Treatment related toxicity - 4 8 week mortality - Overall survival - Relapse-free survival - Predictive factor response treatment - Quality Life measure include self report symptoms assessment sleep pattern Treatment administration Induction therapy Eligible patient treat induction therapy ( decitabine + cytarabine ) University Pittsburgh Cancer Center inpatient leukemia service Shadyside Hospital . Patients receive decitabine 20mg/m2 100mL normal saline ( NS ) intravenously ( IV ) 1 hour daily five day , follow cytarabine 100mg/m2 1000 mL normal saline ( NS ) continuous IV infusion 24 hour 5 day . Treatment discontinue delay follow treatment period : rise serum creatinine &gt; 2x patient baseline upper limit normal ( whichever high ) unless identifiable reversible etiology , ALT , AST total bilirubin &gt; 5x upper limit normal , hold resolution parameter . There parameter dose reduction . Patients persistent disease post-treatment bone marrow aspirate biopsy , undergo repeat cycle induction decitabine follow cytarabine outline . Supportive care include blood product transfusion , antiemetic medication antiviral antifungal medication , empiric antibiotic may use clinical discretion provider . Maintenance therapy Patients complete response ( CR ) proceed decitabine maintenance therapy , treatment decitabine 20mg/m2 100mL normal saline ( NS ) intravenously ( IV ) 1 hour daily five day administer outpatient setting . Maintenance treatment continue disease relapse . Maintenance treatment administer outpatient Hillman Cancer Center , University Pittsburgh Medical Center ( UPMC ) facility able administer chemotherapy supervision Oncologist Evaluations maintenance Phase : During maintenance therapy , complete blood count ( CBC ) w/ diff/platelets , CMP ( Na , K , Cl , carbon dioxide ( CO2 ) , glucose , blood urea nitrogen ( BUN ) , Cr , Ca , Total Protein , Albumin , AST , ALT , Alk Phos , Total Bilirubin ) check cycle day 14 [ +/- 4 day ] . Within 7 day start new cycle , study visit include physical exam , adverse event assessment , CBC comprehensive metabolic panel ( CMP ) . Maintenance cycle 28 day [ +/- 7 day ] . Cycles hold 4 week [ 28 day ] . For start new cycle , grade 3 4 non-hematologic toxicity possibly , probably definitely related decitabine therapy must resolve grade 2 baseline . In addition follow lab parameter must meet start new cycle maintenance : Absolute Neutrophil Count ( ANC ) &gt; = 1000/mm3 Platelets &gt; /= 50,000/mm3 AST ALT &lt; 2 x Uppler Limit Normal ( ULN ) Total billirubin &lt; 2 x ULN Serum creatinine &lt; 2x patient baseline upper limit normal ( whichever high ) [ If lab parameter meet start cycle , lab check minimum per week ] . If start new cycle hold 4 week [ 28 day ] , subject treatment . Other reason delay treatment discuss Principal Investigator .</brief_summary>
	<brief_title>Phase II Study Decitabine Cytarabine Older Patients With Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Age ≥ 70 , age ≥ 60 ineligible treatment standard induction chemotherapy ( base physician discretion patient refusal ) , new diagnosis AML base World Health Organization Classification . 2 . Eastern Cooperative Oncology Group Performance Status 02 3 . Cardiac ejection fraction ≥45 % 4 . Males eligible enter participate study either prior vasectomy agree avoid sexual activity use adequate contraception screen two month post last dose decitabine 1 . Patients acute promyelocytic leukemia 2 . Life expectancy ≤3 month 3 . Prior use hypomethylating agent cytarabine 4 . Uncontrolled , lifethreatening infection respond antimicrobial therapy 5 . Serum creatinine &gt; 2x upper limit normal 6 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &gt; 5x upper limit normal 7 . History psychiatric disorder may compromise compliance protocol allow appropriate inform consent 8 . Patient may receive antineoplastic agent ( hydroxyurea allow ) 9 . Concurrent malignancy . Exception : Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Subjects second malignancy indolent definitively treat may enrol . 10 . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , cardiac disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Phase II</keyword>
	<keyword>decitabine</keyword>
	<keyword>cytarabine</keyword>
	<keyword>old patient</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>AML</keyword>
	<keyword>Newly Diagnosed AML</keyword>
</DOC>